Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 3/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.48 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.48 |
| ▸ | KDM6B | O15054 | 2/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.48 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909641 | 0.89 | KDM4E (0.47) | TOP2AKDM4CKDM3AKDM6BKDM2A | |
| SCHEMBL29717252 | 0.81 | TOP2A (0.56) | TOP2A | |
| SCHEMBL4903739 | 0.79 | SCN10A (0.51) | SMO | |
| SCHEMBL4908579 | 0.78 | KMO (0.48) | KMO | |
| SCHEMBL4901768 | 0.76 | DAO (0.46) | TOP2A | |
| SCHEMBL4912668 | 0.76 | DAO (0.46) | TOP2A | |
| SCHEMBL4909699 | 0.76 | OGT (0.52) | — | |
| SCHEMBL5263131 | 0.75 | HPGD (0.52) | — | |
| SCHEMBL5266303 | 0.73 | DAO (0.45) | — | |
| SCHEMBL4907614 | 0.73 | TOP2A (0.42) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | claimed |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | TOP2A 2/4885KMO 2107/4885KDM5A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.